Pilot study of 4SC-202 affect on 4T1 mouse tumors

Triple Negative Breast Cancer (TNBC) is highly metastatic and invasive, and more effective therapeutics need to be determined. The purpose of this study was to determine the effect of the epigenetic modulator 4SC-202 on the transcriptome of TNBC tumors, formed in the highly metastatic 4T1 model. We hypothesized that 4SC-202 would reduce tumor burden and metastasis, possibly effecting the Cancer Stem Cell (CSC) population. This pilot study (Female Balb/c mice) were maintained as previously described (Messerl et al., 2019). 4T1 cells (2.5 X 104) were injected subcutaneously into the hind limb. In this in vivo experiment examining how 4SC-202 affected tumor growth and metastasis in the highly metastatic murine 4T1 model, the experimental groups received 4SC-202 delivered at two different concentrations (50 mg/kg and 75 mg/kg). Doses were determined at consultation with colleagues at 4SC AG, based on company data. 30 mice were randomly divided into the following groups: 4SC-202 (50 mg/kg), 4SC-202 (75 mg/kg), and Control vehicle saline (0.001% DMSO). Intraperitoneal injections with 4SC-202 and vehicle saline were performed three times a week for 21 days prior to being anesthetized with 5% CO2. At the time of sacrifice, lungs were injected with India Ink. All organs were flash frozen with liquid nitrogen or fixed in 10 % formalin. RNA was isolated from the 4SC-202 (50mg/kg) treated and vehicle control treated group (n = 4).